A F NATIONAL FOUNDATION FOR CANCER RESEARCH LOGO NATIONAL FOUNDATION FOR CANCER RESEARCH LOGO
National Foundation for Cancer Research logo. (PRNewsFoto/National Foundation for Cancer Research)[AS]
BETHESDA AND VIENNA, MD UNITED STATES AND ...
BETHESDA, Md., Sept. 19 /PRNewswire/ -- The National Foundation for
Cancer Research (NFCR), a Bethesda-based leading cancer research charity in
the US, and InhibOx, a computational drug discovery company located in
Oxford, UK, announced today that they have joined forces to launch a
powerful new computational drug screening tool, DrugFinder. This new tool
enables scientists to leverage the power of computer-aided virtual drug
screening technology for novel cancer drug discovery and development and
will accelerate the speed of drug discovery.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070925/CLTU127LOGO )
Using a web-based interface ( http://www.inhibox.com/DrugFinder ),
researchers from around the world will now be able to submit a target (such
as a cancer related protein) structure together with a known inhibitor
compound through the Internet to the DrugFinder service. InhibOx will use
its in-house computing facilities and expertise to screen chemical compound
database against the target. The docking and ligand-based approaches will
be used in combination during the screening process and the "hit" compounds
identified will be returned to the user. It is estimated that this could
speed up the drug discovery process by as much as 4 years. Part of the
service is offered to the public free of charge, providing additional
resources to the public efforts in new drug discovery.
"Our DrugFinder service offers the scientists around world a unique and
powerful virtual screening tool for the development of novel drugs at very
early stage along the development pipe line, which will significantly
reduces the time and costs for new drug discovery and development," said
Dr. Michael Wang, Chief Science Officer of NFCR. "Patients will benefit
from the success of this new initiative," Dr. Wang continued.
DrugFinder service is built upon the successful Peer-to-Peer
Networking, Screensaver-Lifesaver project, which was initiated by NFCR at
the NFCR Center for Computational Drug Discovery in the Chemistry
Department of the University of Oxford in collaboration with United Devices
Inc. in 2001. Ended in 2007, the Screensaver-Lifesaver Project received
tremendous public support from over 3.5 million personal computers in more
than 200 countries and obtained sponsorship at various times from many
corporations including Intel, Microsoft and IBM. In the 7 years of
operation time, the project achieved incredible success and produced very
important and promising results.
InhibOx was founded in 2001 by Professor W. Graham Richards, Chairman
of Chemistry at the University of Oxford and a world leading computational
chemist. The company was a spin-off from the outstandingly successful
Screensaver-Lifesaver project initiated and funded by NFCR. Subsequently,
InhibOx has built up a significant technology platform, including Scopius,
a regularly updated database of millions of commercially available chemical
compounds. InhibOx is committed to discovering and developing entirely
novel, accurate and effective computational methods for drug discovery to
improve the productivity of lead and drug candidate identification. For
more information, please go to http://www.inhibox.com .
Since its founding, the NFCR has spent more than $250 million funding
cancer research and prevention education focused on understanding how and
why cells become cancerous. NFCR is dedicated to funding scientists who are
discovering cancer's molecular mysteries and translating these discoveries
into therapies that hold the hope for curing cancer. For more information,
visit http://www.NFCR.org or call (800) 321-CURE.
SOURCE The National Foundation for Cancer Research